scispace - formally typeset
O

Ora Paltiel

Researcher at Hebrew University of Jerusalem

Publications -  202
Citations -  6428

Ora Paltiel is an academic researcher from Hebrew University of Jerusalem. The author has contributed to research in topics: Population & Cohort study. The author has an hindex of 40, co-authored 184 publications receiving 5534 citations. Previous affiliations of Ora Paltiel include University of Catania & Hadassah Medical Center.

Papers
More filters
Journal ArticleDOI

Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma.

TL;DR: An integrative analysis of whole-exome sequencing and transcriptome sequencing in a cohort of DLBCL patients is performed to comprehensively define the landscape of 150 genetic drivers of the disease and their functional roles to identify new therapeutic opportunities in the disease.
Journal ArticleDOI

Etiologic Heterogeneity Among Non-Hodgkin Lymphoma Subtypes: The InterLymph Non-Hodgkin Lymphoma Subtypes Project

Lindsay M. Morton, +93 more
TL;DR: Using a novel approach to investigate etiologic heterogeneity among NHL subtypes,risk factors that were common among subtypes as well as risk factors that appeared to be distinct among individual or a few subtypes are identified, suggesting both subtype-specific and shared underlying mechanisms.
Journal ArticleDOI

Determinants of the Use of Complementary Therapies by Patients With Cancer

TL;DR: Significant associations between CT use and attending supportive psychotherapy, unmet needs, helplessness, and worse emotional and social function indicate considerable distress, suggesting that increased attention to psychosocial needs within oncologic settings is warranted.
Journal ArticleDOI

Long-term mortality after preeclampsia.

TL;DR: It is suggested that the observation of a normal blood pressure after preeclampsia should not discourage the search for other cardiovascular risk factors or abrogate the need for other preventive measures.
Journal ArticleDOI

Human menopausal gonadotropin and the risk of epithelial ovarian cancer

TL;DR: It is concluded that the use of ovulation induction agents, in particular hMG, may increase the risk of epithelial ovarian tumors.